Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
On the Downside Radar. Closed at $3.54, 51% below $7.18, its close on the day of its Sep 21 private placement. Of biotech stocks this far below their close on the day of a recent offering, 76% were lower 60 trading days later (median -29%). How we know
$5MCash on Hand
4.4mo Cash Runway
Follow GTBP by emailGet an email when GTBP reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about GTBP, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 12, 2026 ·
Shareholder vote Stockholders approved eliminating obsolete preferred stock references, raising authorized common shares from 25,000,000 to 250,000,000, and issuance of 19.99% or more of outstanding common stock tied to the September 14, 2026 Securities Purchase Agreement, including Series M Preferred conversion and warrant exercise. Form 8-K · SEC filing
Oct 20, 2026 ·
Financing Registers up to 13,502,835 shares of common stock for resale by selling stockholders, including conversion shares for Series M and Series L preferred, warrant shares, and dividend shares. The company receives no proceeds from these sales. Shares closed at $6.69 on October 19, 2026. Form 424B3 · SEC filing
Oct 9, 2026 ·
Financing GT Biopharma filed a preliminary S-1 registering up to 13,502,835 shares of common stock for resale by selling stockholders, arising from earlier Series L and Series M preferred stock placements and dividend shares. The company will receive no proceeds from the resale. The stock closed at $5.96 on October 8, 2026. Form S-1 · SEC filing
Sep 25, 2026 ·
Listing GT Biopharma regained compliance with Nasdaq's $1.00 minimum bid price requirement on September 22, 2026, after its common stock closed above $1.00 for at least ten consecutive business days. The company had received a 180-day extension in May 2026 to regain compliance. Form 8-K · SEC filing
Sep 21, 2026 ·
Financing Company completed a private placement of Series M 10% Convertible Preferred Stock and warrants, with the offering increased to $7,750,000 in purchase price after a new purchaser joined and the preferred stock authorization was raised to 43,287 shares. Form 8-K · SEC filing
Sep 15, 2026 ·
Financing Entered a securities purchase agreement for a private placement of Series M 10% convertible preferred stock and warrants, for an aggregate purchase price of $7,450,000. Purchasers may also elect up to $30,000,000 more. Conversion and exercise price is $6.10, with full ratchet price protection. Form 8-K · SEC filing
Sep 3, 2026 ·
Restructuring GT Biopharma filed Certificates of Elimination on September 2, 2026, removing 11 series of preferred stock from its charter after Series C converted and no preferred shares remained outstanding. It also effected a 1-for-25 reverse stock split effective September 8, 2026, cutting authorized common to 25,000,000. Form 8-K · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
GTBP holds $5M in cash and short-term investments (as of Jun 30, 2026) and burns about $3.4M/quarter from operations,
an estimated runway of 4.4 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:45 · Elevated
Cash runway 10 months +30
Going-concern doubt in the latest 10-Q +15These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued.10-Q, Nov 2026
Share count 2,137,240 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full GTBP picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GTBP and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.